An interventional study of Standardized research e-cigarette (SREC) in Electronic Cigarette Use, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 288 studies in Vaping with a site in United States — 66 open to participants now, 74 under way, 1 of them phase 3. Vaping · United States.
Among the 288 studies in Vaping with a site in United States, this one is the 174th largest by enrollment of the 258 interventional ones that give a count, is one of 31 that started in 2024, is one of 206 with no phase, and was the 179th registered.
404 studies on the registry are indexed under Vaping; 97 are open to participants now.
Browse Vaping studies →66 of the 288 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of Nebraska · Sites in United States
Ages 15–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
288 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 21 · Phase 3 4 · Phase 4 12
First in 2013; this study’s year is marked. 31 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 79 across 324 interventional studies indexed under Vaping.
Median enrollment 71 across the 258 interventional studies, 110 across the 30 observational. Of the 202 that completed or were terminated, 87 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 288 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 8 studies filed under Vaping — fewer than ten, so there is no comparison to draw.
31 of the studies in Vaping with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322432VapeAwayThe CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | 2026-12 |
| NCT06159608Anna Stanhewicz, PhDSex Differences in the Vascular Effects of E-cigarette Use | 2026-12 |
| NCT04661683University of California, Los AngelesSecondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol | 2026-12-15 |
| NCT07553585Yale UniversitySurvey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes | 2026-12-15 |
| NCT04907136Florida International UniversityDeveloping and Testing Health Warning Labels on the ENDS Device | 2026-12-30 |
Add all 31 to your calendar (.ics) → With an account.
Among the 288 studies in Vaping with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to conduct a pilot randomized waitlist-controlled trial to assess the feasibility, acceptability, and preliminary effects of substituting the NIDA standardized research e-cigarette (SREC) for combusted cigarettes in MOUD-TUD who are not ready to quit smoking. A waitlist controlled RCT using a mixed-methods sequential explanatory design will investigate the impact of SREC provision on: 1) tobacco use behavior (e.g., cigarettes per day [primary outcome], SREC use), 2) biomarkers (e.g., carbon monoxide, anabasine), 3) cigarette dependence and withdrawal, and 4) short-term health effects and tolerability (e.g., respiratory symptoms, substance use). In the proposed RCT, N=40 adults stable on MOUD with buprenorphine who report daily smoking recruited from MGH primary care practices will be randomly assigned to receive the SREC for 8 weeks, either immediately (iSREC), or after an 8-week delay (waitlist control [WLC]). They will be followed an additional 4 weeks after SREC provision ends (to 12 weeks in iSREC and 20 weeks in WLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
18 years of age
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Those randomized to the iSREC group will be provided a free 8-week supply of standardized research e-cigarettes (SRECs) and asked to try to switch completely to the SREC.
Device: Standardized research e-cigarette (SREC)
Those in the WLC condition will receive SREC provision after an 8-week delay.
Device: Standardized research e-cigarette (SREC)
Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
Also known as: SREC
Cigarettes Smoked Per Day
Change in cigarettes smoked per day (CPD) between randomized groups. Change in mean number of CPD in the past 7 days from start to end of the e-cigarette provision period comparing between randomized groups (iSREC group vs. WLC).
Time frame: Baseline to Week 8
Study Enrollment
Proportion of those screened identified as eligible. Proportion of those identified as eligible at screening who enroll in trial.
Time frame: Screening to Baseline
E-cigarette Use During E-cigarette Provision
Difference between randomized groups in days per week of EC use during e-cigarette provision.
Time frame: Baseline to Week 8 for iSREC and WLC
Breath Carbon Monoxide
Change in expired air carbon monoxide (CO) during e-cigarette provision.
Time frame: Baseline to Week 8
Anabasine
Change in the percentage of participants who met anabasine-based tobacco abstinence criteria during e-cigarette provision.
Time frame: Baseline to Week 8
Study Completion
Proportion of patients who complete the trial, defined as completing the final follow-up assessment (12 weeks for iSREC and 20 weeks for WLC)
Time frame: Week 12 for iSREC, Week 20 for WLC
| Milestone | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) |
|---|---|---|
| Started | 22 | 19 |
| Completed | 18 | 16 |
| Not completed | 4 | 3 |
Change in cigarettes smoked per day (CPD) between randomized groups. Change in mean number of CPD in the past 7 days from start to end of the e-cigarette provision period comparing between randomized groups (iSREC group vs. WLC).
| Number of Cigarettes per Day | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) |
|---|---|---|
| Cigarettes Smoked Per Day | 8.1 ± 4.7 | 1.4 ± 7.6 |
Proportion of those screened identified as eligible. Proportion of those identified as eligible at screening who enroll in trial.
| Participants | Total |
|---|---|
| Number of Participants Screened Eligible | 113 |
| Number of Participants Enrolled | 41 |
Difference between randomized groups in days per week of EC use during e-cigarette provision.
| Days per week with e-cigarette use | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) |
|---|---|---|
| E-cigarette Use During E-cigarette Provision | 6.2 ± 1.2 | 1.8 ± 2.5 |
Change in expired air carbon monoxide (CO) during e-cigarette provision.
| ppm | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) |
|---|---|---|
| Breath Carbon Monoxide | -10.6 ± 9.8 | -6.1 ± 11.0 |
Change in the percentage of participants who met anabasine-based tobacco abstinence criteria during e-cigarette provision.
| Percent participants abstinent | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) |
|---|---|---|
| Baseline Anabasine Abstinence | 14 | 28 |
| Week 8 Anabasine Abstinence | 35 | 29 |
Proportion of patients who complete the trial, defined as completing the final follow-up assessment (12 weeks for iSREC and 20 weeks for WLC)
| Participants | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) |
|---|---|---|
| Study Completion | 18 | 16 |
Collected over From enrollment to end of follow-up (SREC week 12, WLC week 20). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Start (iSREC, Standardized Research Electronic Cigarette) | 0/22 (0%) | 0/22 (0%) | 8/22 (36.4%) |
| Waitlist Control (WLC) During SREC Provision | 0/19 (0%) | 0/19 (0%) | 4/19 (21.1%) |
| Waitlist Control (WLC) During Control Period | 0/19 (0%) | 0/19 (0%) | 6/19 (31.6%) |
| Event | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | Waitlist Control (WLC) During SREC Provision | Waitlist Control (WLC) During Control Period |
|---|---|---|---|
| DepressionPsychiatric disorders | 1/22 | 1/19 | 2/19 |
| StressGeneral disorders | 1/22 | 2/19 | 1/19 |
| Body painMusculoskeletal and connective tissue disorders | 1/22 | 0/19 | 1/19 |
| Common ColdRespiratory, thoracic and mediastinal disorders | 0/22 | 1/19 | 1/19 |
| Manic EpisodePsychiatric disorders | 0/22 | 0/19 | 1/19 |
| Hidradenitis FlareSkin and subcutaneous tissue disorders | 0/22 | 1/19 | 0/19 |
| InfectionInfections and infestations | 1/22 | 0/19 | 1/19 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/22 | 0/19 | 1/19 |
| Root Canal PainGeneral disorders | 0/22 | 1/19 | 0/19 |
| InsomniaPsychiatric disorders | 1/22 | 0/19 | 0/19 |
| Age, Continuous(Years) | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) | Total |
|---|---|---|---|
| Mean | 52 ± 12 | 48 ± 11 | 50 ± 12 |
| Sex: Female, Male(Participants) | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 18 | 13 | 31 |
| Race (NIH/OMB)(Participants) | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 19 | 17 | 36 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Immediate Start (iSREC, Standardized Research Electronic Cigarette) | SREC Waitlist Control (WLC) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 22 | 17 | 39 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in Dec 2025, 18 months.
Results were first posted in Oct 2026, 9 months after primary completion.
Of 184 non-industry interventional studies with no phase under Vaping, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's 18 months is close to that.
Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 6 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →